U.S. Food and Drug Administration (FDA) in its application of the Indian company was recalling a batch of 34,368 bottles that the drug did not meet the specifications of the impurities in the station in the stability of nine months.
The lot, which is remembered, expires in July next year, the report said. The company produces the drug at its plant in Goa.
The memory comes from the FDA Class II means that the drug may cause temporary or reversible adverse health clinically, but unlikely to have serious adverse health consequences.
When contacted, Lupin, a company spokesman said: "We had a lot of impurities losartan potassium tablets together with the stability of full-time as a precautionary measure, we voluntarily recalled batch is limited to an element Remember The total value of the product is irrelevant ...."
Lupin's shares today closed at Rs 446 on the Bombay Stock Exchange, down 0.42% at the previous close.